Abstract
Inhibition of the proinflammatory cytokine TNF-α has been shown to be an effective strategy for treating inflammatory dermatoses. Etanercept competitively inhibits the interaction of TNF, interrupting the proinflammatory cytokine cascade and preventing TNF mediated cellular responses. The success of etanercept in a wide range of dermatologic conditions especially in psoriasis gives a new hope in dermatological therapy field. This article reviews the pharmacokinetic properties, safety profile, administration route and efficacy in different dermatological conditions of etanercept.
Keywords: tumour necrosis factor aplha, Cytokines, TNF inhibitors, Psoriasis, Inflammatory Diseases
Related Journals
Related Books
Quick Guide in History Taking and Physical Examination
Frontiers in Clinical Drug Research: Anti-Infectives
Osteoporosis, Osteoarthritis and Rheumatoid Arthritis: An Agonizing Skeletal Triad
Natural Products for Treatment of Skin and Soft Tissue Disorders
Common Pediatric Diseases: Current Challenges
Recent Advances in the Application of Marine Natural Products as Antimicrobial Agents
Advanced Pharmacy
Plant-derived Hepatoprotective Drugs
Cancer Genes
The Role of Chromenes in Drug Discovery and Development
8